WO2011040495A1 - ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物 - Google Patents
ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物 Download PDFInfo
- Publication number
- WO2011040495A1 WO2011040495A1 PCT/JP2010/066997 JP2010066997W WO2011040495A1 WO 2011040495 A1 WO2011040495 A1 WO 2011040495A1 JP 2010066997 W JP2010066997 W JP 2010066997W WO 2011040495 A1 WO2011040495 A1 WO 2011040495A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heparanase activity
- heparanase
- activity inhibitor
- heparan sulfate
- pharmaceutical composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the present invention relates to a heparanase activity inhibitor containing 4-alkylresorcinol as an active ingredient, and a wrinkle improving agent and a pharmaceutical composition using the heparanase activity inhibitor.
- Heparanase is an enzyme that specifically degrades the heparan sulfate chain of various heparan sulfate proteoglycans, and is present in various cells such as platelets, leukocytes, endothelial cells, smooth muscle cells and the like. In particular, in the skin, it is produced in epidermal keratinocytes constituting the epidermis, fibroblasts in the dermis, vascular endothelial cells, and the like. In addition, it is known that production is increased also in various cancer cells.
- Heparan sulfate proteoglycan which is a degradation substrate for heparanase, is a macromolecule present on the cell surface and extracellular matrix of various animal tissues, and it is a growth factor bound to heparan sulfate (bFGF (basic fibroblast growth factor) And HGF (hepatocell growth factor), VEGF (vascular endothelial cell growth factor), HB-EGF (heparin binding EGF-like growth factor), etc. are known to have functions such as extracellular accumulation.
- bFGF basic fibroblast growth factor
- HGF hepatocell growth factor
- VEGF vascular endothelial cell growth factor
- HB-EGF heparin binding EGF-like growth factor
- the epidermal basement membrane present at the boundary between the epidermis and the dermis contains perlecan, which is one of the heparan sulfate proteoglycans, and by binding the heparan sulfate-binding growth factor to the epidermal basement membrane, the epidermis and the dermis are separated. Control the movement of growth factors between In addition, perlecan regulates the action of growth factors on epidermal basal cells bound to basement membrane, and has been shown to be essential for good growth and differentiation of the epidermis.
- degradation of the heparan sulfate chain of perlecan by activation or upregulation of heparanase disrupts the release of the accumulated growth factor and the control of the growth factor between the epidermis and the dermis, resulting in the disruption of epidermal differentiation / growth control. And causes thickening of the dermis to promote the formation of wrinkles (see PCT / JP2009 / 056717).
- inhibition of heparanase activity suppresses the release of growth factors associated with the degradation of heparan sulfate, which makes it possible to control the transfer of growth factors between the epidermis and the dermis, which in turn leads to anti-skin activity. It is thought to be useful for aging.
- Heparanase has also been suggested to be associated with the grade of cancer.
- cancer cells having high production of heparanase are known to be highly proliferative and metastatic and to have high ability to induce angiogenesis (Non-patent Document 1).
- heparanase has an action to promote wound healing (Non-patent Document 2). Therefore, if heparanase activity can be effectively inhibited, it is also effective in applications such as suppression of growth or metastasis of cancer cells and suppression of angiogenesis.
- the present invention was made in view of the above problems, and it is an object of the present invention to provide a heparanase activity inhibitor capable of efficiently inhibiting heparanase activity, and a wrinkle improving agent and a pharmaceutical composition using such heparanase activity inhibitor. I assume.
- the present inventors have found that a given 4-alkylresorcinol efficiently inhibits heparanase activity. That is, the gist of the present invention is as follows.
- 4-alkyl resorcinol represented by the following formula (I) (Wherein, R represents a linear or branched alkyl group having 1 to 6 carbon atoms) Heparanase activity inhibitor which comprises as an active ingredient.
- R represents a linear or branched alkyl group having 1 to 6 carbon atoms
- Heparanase activity inhibitor which comprises as an active ingredient.
- the heparanase activity inhibitor according to (2) wherein the 4-alkyl resorcinol of the formula (I) is 4-isobutyl resorcinol.
- a pharmaceutical composition for treating, ameliorating or preventing a condition or symptom associated with heparanase activity which comprises the heparanase activity inhibitor of (1) to (3) as an active ingredient.
- the pharmaceutical composition of (4) which is used for wound healing, suppression of proliferation or metastasis of cancer cells, or suppression of angiogenesis.
- a wrinkle improving agent that prevents or suppresses the formation of wrinkles, and comprises the heparanase activity inhibitor (1) to (3) as an active ingredient.
- the heparanase activity inhibitor of the present invention can efficiently inhibit heparanase activity, it can be used, for example, as an active ingredient of a wrinkle improving agent, for preventing or suppressing the formation of wrinkles (in particular, large wrinkles), or a pharmaceutical composition
- a wrinkle improving agent for preventing or suppressing the formation of wrinkles (in particular, large wrinkles)
- a pharmaceutical composition As an active ingredient of the substance, it can be suitably used for treatment, amelioration or prevention of a condition or a symptom associated with heparanase activity.
- FIG. 3 shows a "heparan sulfate decomposition model" (heparan sulfate (-)) containing no heparan sulfate in the basement membrane sheet, and Fig.
- FIG. 3 (b) shows a "normal model” not containing heparan sulfate in the basement membrane sheet. (Heparan sulfate (+)) is represented. It is a graph showing the evaluation result of the permeability of VEGF using the simulated skin model of FIG. 3 (a), (b). It is a photograph showing the evaluation result of angiogenesis using the simulated skin model of FIG. 3 (a), (b). It is a graph showing the analysis result of the blood vessel area in the photograph of FIG.
- the present inventors have identified resorcinol derivatives that significantly suppress heparanase activity.
- the present invention has been achieved.
- JP-A-2-49715 and JP-A-2006-124358 disclose that a specific resorcinol derivative is used as a skin lightening agent, and JP-A-2007-254412 wrinkles a specific resorcinol derivative. It is disclosed to use it for external skin preparations for the prevention and improvement of (1), but none disclose the inhibitory effect of heparanase activity.
- the inhibition of heparanase activity suppresses the degradation of the heparan sulfate chain of the heparan sulfate proteoglycan, so the amount of heparan sulfate (such as heparin) in cells is maintained at a relatively high value.
- the heparanase activity inhibitor of the present invention comprises 4-alkylresorcinol represented by the following formula (I) as an active ingredient.
- R represents a linear or branched alkyl group having 1 to 6 carbon atoms. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, sec-hexyl and the like.
- linear or branched alkyl groups having 2 to 4 carbon atoms such as ethyl, n-propyl, isopropyl, n-butyl and isobutyl are preferable, and isobutyl is particularly preferable. That is, 4-isobutyl resorcinol is most preferable as the 4-alkyl resorcinol of the formula (I).
- the method for producing the 4-alkylresorcinol of the formula (I) is not limited, but free of saturated carboxylic acid or saturated carboxylic acid halide and resorcinol in the presence of Lewis acid such as zinc chloride or aluminum chloride
- Lewis acid such as zinc chloride or aluminum chloride
- the method of reaction with Del-Crafts and reduction of 4-acylresorcinol formed with zinc amalgam / hydrochloric acid (Japanese Patent Publication No. 6-51619, US Patent No. 2093778) or alumina as catalyst, resorcinol and n- A method of directly producing 4-n-hexyl resorcinol by reacting with hexanol at 200 to 400 ° C.
- the heparanase activity inhibitor of the present invention may contain only one 4-alkylresorcinol of the formula (I) alone, but any combination of two or more 4-alkylresorcinols of the formula (I) may be used. And in proportions.
- the content of 4-alkylresorcinol of the formula (I) in the heparanase activity inhibitor of the present invention is not particularly limited as long as it is an amount sufficient to effectively exhibit the heparanase activity inhibitory action, and heparanase activity inhibition It may be appropriately selected according to the use of the agent.
- the ratio of 4-alkylresorcinol of the formula (I) to the whole heparanase activity inhibitor is usually 0.0001% by mass or more, in particular 0.0001% by mass or more, and usually 1% by mass or less, especially 0 It is preferable that the amount be 2% by mass or less.
- the total amount thereof may be within the above range.
- the heparanase activity inhibitor of the present invention is added in addition to the 4-alkylresorcinol of the formula (I) as long as the 4-alkylresorcinol of the formula (I) does not substantially impair the inhibitory action of heparanase activity. It may contain other optional ingredients. Other components include other compounds (other active ingredients) having an inhibitory effect on heparanase activity, and pharmaceutically acceptable carriers and / or adjuvants. One of these other components may be used alone, or two or more thereof may be used in any combination and ratio.
- the heparanase activity inhibitor of this invention is not limited, It can be used as cosmetics, a quasi-drug, a pharmaceutical composition etc., or those compounding components.
- the pharmaceutical composition (the pharmaceutical composition of the present invention) containing the heparanase activity inhibitor of the present invention as an active ingredient can be used for treating, ameliorating or preventing various conditions or symptoms associated with heparanase activity.
- the “state or condition related to heparanase activity” for example, aging of skin, growth or metastasis of cancer cells, angiogenesis and the like can be mentioned. Therefore, the pharmaceutical composition of the present invention is suitably used, for example, for the improvement or prevention of skin aging (anti-aging), the suppression of growth or metastasis of cancer cells, the suppression of angiogenesis and the like.
- Skin aging is an important factor macroscopically, but in addition, oxidation, dryness, sunlight (ultraviolet light), etc. are also mentioned as direct factors related to skin aging.
- As specific phenomena of skin aging reduction of mucopolysaccharides including hyaluronic acid, cross-linking reaction of collagen, cell damage by ultraviolet light and the like are known.
- Various studies have been conducted for the purpose of suppressing or improving wrinkles, wrinkles, sagging, etc. of the skin caused by skin injury or skin aging caused by exposure to ultraviolet light. As a result, for example, promotion of production of hyaluronic acid (Japanese Patent Laid-Open No.
- the present inventors as a simulated skin model are a normal model containing heparan sulfate in the basement membrane and heparan sulfate degradation which does not contain heparan sulfate in the basement membrane.
- Models were created to assess VEGF permeability and angiogenesis. As a result, it was revealed that the permeability of VEGF increased in the heparan sulfate degradation model and angiogenesis was induced as compared with the normal model (see FIGS. 3 to 6).
- anti-aging refers to skin changes associated with the release of heparan sulfate binding growth factor due to degradation of heparan sulfate of basement membrane proteoglycan due to aging or photoaging, specifically, epidermal differentiation abnormality, dermis
- suppressing angiogenesis, lymphangiectasia and elastin degradation it means preventing and improving skin wrinkles, sagging, hardening and the like, and maintaining a resilient and youthful healthy skin condition.
- administration route and dosage form of the pharmaceutical composition of the present invention are not limited, and may be appropriately selected depending on the use.
- administration routes include oral administration, parenteral administration (intravenous administration, intraperitoneal administration and the like), topical administration (external skin use and the like) and the like.
- oral dosage forms solid preparations such as tablets, coated tablets, coated tablets, granules, powders, capsules (eg hard or soft gelatin capsules) etc., liquid preparations such as internal liquid preparations, syrups (solutions, Suspension) and the like.
- parenteral administration forms such as injection solutions may be mentioned.
- solutions in the case of topical administration, solutions, solubilization, emulsion, powder dispersion, water-oil bilayer, water-oil-powder trilayer, etc., patch, ointment, cream, milky lotion, lotion, gel And aerosols.
- the compounding amount of the heparanase activity inhibitor of the present invention in the pharmaceutical composition of the present invention is also not limited, and may be appropriately selected according to the use, dosage form, administration form and the like of the pharmaceutical composition.
- the pharmaceutical composition of the present invention is a skin external preparation
- the blending amount of the heparanase activity inhibitor of the present invention is usually 0.0001 mass% or more as dry mass (solid content mass) in the total amount of the skin external preparation.
- the range of 0.0001% by mass or more, usually 1% by mass or less, and particularly 0.2% by mass or less is preferable.
- the compounding amount is less than the above range, the effect of the heparanase activity inhibitor of the present invention tends not to be sufficiently exhibited, but even if it is compounded exceeding the above range, improvement in the effect according to the compounding amount is not obtained There is a tendency, and also the formulation tends to be difficult.
- the pharmaceutical composition of the present invention may further contain one or two or more other ones as long as the heparanase activity inhibitor of the present invention does not substantially impair the inhibitory activity of heparanase activity.
- Other components are not particularly limited and may be appropriately selected depending on the use of the pharmaceutical composition, dosage form, administration form and the like, and examples include pharmaceutically acceptable carriers and / or adjuvants. .
- auxiliaries for example, diluents, binders, disintegrants, thickeners, dispersants, resorption accelerators, taste masking agents, buffers, surfactants, solubilizers, preservatives, emulsifiers, tonicity agents , Stabilizers, pH adjusters and the like.
- components generally used for external preparations such as skin lightening agents, moisturizers, antioxidants, oil components, ultraviolet light absorbers, surfactants, A tackifier, an alcohol, a powder component, a coloring agent, an aqueous component, water, various skin nutrients and the like can be appropriately blended as needed.
- sedeters such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, preservatives such as methyl paraben, ethyl paraben, butyl paraben, caffeine, tannin, Verapamil, tranexamic acid and derivatives thereof, licorice extract, glabridin, hot water extract of fruit of cullin, various herbal medicines, drugs such as tocopherol acetate, glycyrrhizinic acid and derivatives thereof or salts thereof, vitamin C, magnesium ascorbate phosphate, Ascorbic acid glucoside, whitening agents such as arbutin and kojic acid, sugars such as glucose, fructose, mannose, sucrose and trehalose, vitamin A derivatives such as retinoic acid, retinol, retinol acetate and retinol palmitate are also suitable. It can be formulated.
- the wrinkle improving agent when used for cosmetics or quasi-drugs, it is preferable to use the wrinkle improving agent as an active ingredient.
- the wrinkle improvement agent which mix
- the wrinkles are divided into fine wrinkles formed in the epidermis by drying and the like and large wrinkles formed in the dermis by ultraviolet light and the like, and the wrinkle improving agent of the present invention can be applied to any of them. However, it is particularly effective for the improvement of large wrinkles caused by ultraviolet light and the like.
- the administration route and the dosage form of the wrinkle improving agent of the present invention are not limited, and may be appropriately selected depending on the use.
- Examples of administration routes include oral administration, topical administration and the like.
- Examples of dosage forms include, in addition to the various dosage forms described above for pharmaceutical compositions, addition to various food and beverage products for oral administration.
- the compounding amount of the heparanase activity inhibitor of the present invention in the wrinkle improving agent of the present invention is also not limited, and may be appropriately selected according to the application, dosage form, administration form and the like of the wrinkle improving agent.
- the wrinkle improving agent of the present invention includes one or more other ones or 2 in addition to the heparanase activity inhibitor of the present invention, as long as the heparanase activity inhibitor of the present invention does not substantially impair the inhibitory activity of heparanase activity. More than any species of optional ingredients can be blended.
- the other components are not particularly limited, and may be appropriately selected according to the use, dosage form, administration form and the like of the wrinkle improving agent.
- A431 cells (invasive human epithelial cancer cells) were cultured in DMEM (Dulbecco's modified Eagle's medium) containing 10% serum. The cultured cells are solubilized in Lysis Buffer (50 mM Tris, 0.5% Triton X-100, 0.15 M sodium chloride, pH 4.5), recovered with a scraper, and then pipetted on ice. Let stand for 30 minutes. Thereafter, the insoluble matter was removed by centrifugation at 10,000 rpm for 10 minutes, and the supernatant was recovered as a cell extract. The amount of protein in this cell extract was measured with a BCA protein assay kit (BCA Protein Assay Kit, PIERCE, CA46141).
- the above-mentioned A431 cell extract was diluted to 500 ⁇ g / mL in assay buffer (50 mM HEPES, 50 mM sodium acetate, 150 mM sodium chloride, 9 mM calcium chloride, 0.1% BSA). Subsequently, the compound to be tested is dissolved in DMSO, added to this diluted cell extract at a ratio of 0.0005% by mass, 0.005% by mass and 0.05% by mass, and mixed. A sample solution was prepared (final concentration of DMSO 5%). The control solution was mixed with DMSO to a final concentration of 5% with respect to the diluted cell extract.
- assay buffer 50 mM HEPES, 50 mM sodium acetate, 150 mM sodium chloride, 9 mM calcium chloride, 0.1% BSA.
- sample solution and control solution were seeded at a rate of 100 ⁇ L / well on a biotinylated heparan sulfate immobilized plate. React at 37 ° C. for 2 hours, wash 3 times with PBS-T, and add 10,000-fold diluted HRP-avidin (Vector, A-2004) / PBS-T at a rate of 100 ⁇ L / well, 37 ° C. It was allowed to react for 1 hour. After washing again with PBS-T three times, 100 ⁇ L / well of TMB reagent (BIO-RAD, 172-1066) is added and reacted, after stopping the reaction with 1 N sulfuric acid, absorbance at 475 nm (OD 475) was measured.
- TMB reagent BIO-RAD, 172-1066
- the compound to be tested is not added to serial dilutions (cell extract concentration 500 ⁇ g / mL, 50 ⁇ g / mL, 5 ⁇ g / mL, 0.5 ⁇ g / mL) of the above-mentioned A431 cell extract with assay buffer, DMSO was added to a final concentration of 5% and mixed (solution for calibration curve).
- the treatment for the standard curve solution was carried out after seeding on a biotinylated heparan sulfate-immobilized plate in the same manner as described above, and the OD 475 was measured.
- a calibration curve of protein concentration is prepared based on the value of OD 475 of the calibration curve solution, and using this calibration curve, each sample solution is obtained from the value of OD 475 of the sample solution to which the test compound is added at each addition concentration. Protein concentration was calculated. Furthermore, the protein concentration was similarly calculated for the control solution. The percent inhibition of heparanase activity of each sample solution was determined from the ratio (%) between the protein concentration of each sample solution and the protein concentration of the control solution.
- Japanese Patent Application Publication No. 2003-502054 refer to Japanese Patent Application Publication No. 2003-502054.
- Heparanase activity was evaluated in the same manner as Example 1 based on the obtained OD 475 value. The results are shown in FIG. It was revealed that heparanase was significantly activated in the ultraviolet-irradiated group as compared with the control not irradiated with ultraviolet light.
- the simulated skin model thus obtained can be used as an evaluation system for evaluating the permeability and angiogenesis of VEGF by the presence or absence of heparan sulfate in a sheet regarded as a basement membrane (hereinafter referred to as "basement membrane sheet").
- base membrane sheet a simulated skin model containing heparan sulfate in a basement membrane sheet
- heparan sulfate decomposition model a simulated skin model containing heparan sulfate in a basement membrane sheet.
- VEGF aqueous solution 10 ⁇ g / mL is added to the epidermal side (within the insert) of each model and allowed to stand at room temperature for 3 hours, and the VEGF concentration in the dermal side wells is It detected with VEGF ELISA kit (R & D systems).
- VEGF ELISA kit R & D systems
- angiogenesis 100 ⁇ g / mL of VEGF aqueous solution is added to the epidermal side (within the insert) of each model, and after being set in an angiogenesis kit (Kurabo) and cultured for 11 days, Optical micrographs were taken. The obtained image is shown in FIG. In the heparan sulfate degradation model, significant angiogenesis was observed in a concentration-dependent manner, but no angiogenesis was observed in the normal model.
- the blood vessel area of the image of FIG. 5 was analyzed using analysis software for angiogenesis kit (Kurabo Co., Ltd.). The results are shown in FIG. In the heparan sulfate degradation model, a marked increase in blood vessel area was observed as compared with the normal model, which revealed that angiogenesis was significantly occurring.
- the present invention relates to the treatment, amelioration or prevention of a condition or condition associated with heparanase activity, specifically amelioration or prevention of skin aging (anti-aging), wound healing, suppression of cancer cell proliferation or metastasis, angiogenesis It is suitably used in the field of pharmaceutical compositions and the like for the purpose of suppression and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
本発明は上記課題に鑑みてなされたもので、ヘパラナーゼ活性を効率的に阻害し得るヘパラナーゼ活性阻害剤と、斯かるヘパラナーゼ活性阻害剤を用いたしわ改善剤及び医薬組成物を提供することを目的とする。
すなわち、本発明の要旨は以下の通りである。
(1)下記式(I)で示される4-アルキルレソルシノール
を活性成分として含んでなるヘパラナーゼ活性阻害剤。
(2)式(I)中、Rが炭素数2~4の直鎖又は分岐のアルキル基である、(1)のヘパラナーゼ活性阻害剤。
(3)式(I)の4-アルキルレソルシノールが、4-イソブチルレソルシノールである、(2)のヘパラナーゼ活性阻害剤。
(4)ヘパラナーゼ活性に関連する状態又は症状を治療、改善又は予防するための医薬組成物であって、(1)~(3)のヘパラナーゼ活性阻害剤を有効成分として含んでなる医薬組成物。
(5)創傷治癒、癌細胞の増殖若しくは転移の抑制、又は血管新生の抑制に用いられる、(4)の医薬組成物。
(6)しわの形成を予防又は抑制するしわ改善剤であって、(1)~(3)のヘパラナーゼ活性阻害剤を有効成分として含んでなるしわ改善剤。
本発明のヘパラナーゼ活性阻害剤における、式(I)の4-アルキルレソルシノールの含有量は、ヘパラナーゼ活性の阻害作用を有効に発揮するのに十分な量であれば特に限定されず、ヘパラナーゼ活性阻害剤の用途に応じて適宜選択すればよい。但し一般には、ヘパラナーゼ活性阻害剤全体に対する式(I)の4-アルキルレソルシノールの比率を、通常0.0001質量%以上、中でも0.0001質量%以上、また、通常1質量%以下、中でも0.2質量%以下とするのが好ましい。2種以上の式(I)の4-アルキルレソルシノールを用いる場合は、それらの合計量が上記範囲を満たすようにすればよい。
本発明のヘパラナーゼ活性阻害剤を有効成分として配合した医薬組成物(本発明の医薬組成物)は、ヘパラナーゼ活性に関連する種々の状態又は症状の治療、改善又は予防に用いることができる。ここで「ヘパラナーゼ活性に関連する状態又は症状」としては、例えば皮膚の老化、癌細胞の増殖又は転移、血管新生等が挙げられる。よって本発明の医薬組成物は、例えば皮膚の老化の改善又は予防(抗老化)、癌細胞の増殖又は転移の抑制、血管新生の抑制等に、好適に用いられる。
皮膚傷害を原因とする、或いは紫外線暴露による皮膚老化を原因とする、肌のしわ、こじわ、たるみ等の抑制、改善を目的とした様々な研究がなされている。その結果、例えばヒアルロン酸の産生促進(特開2001-163794号公報)、マトリックス・金属プロテイナーゼ(MMP)の産生・活性の抑制(特表2000-503660号公報)、コラーゲンの産生促進、エステラーゼの活性の阻害(特開平11-335235号公報)、血管新生の抑制(WO03/84302、特願2003-581562号公報)、リンパ管拡張抑制(K. Kajiya et al., Am. J. Pathol., 2006, 169(4): 1496-1503.参照)等が、有効であることが解明されている。
実際、本発明者等は以前、ヘパラナーゼ活性阻害剤を小じわモデルに塗布することで、有意な抗しわ効果があることを明らかにしている(PCT/JP2009/056717)。
本発明のしわ改善剤における本発明のヘパラナーゼ活性阻害剤の配合量も限定されず、しわ改善剤の用途、剤型、投与形態等に応じて適宜選択すればよい。
以下、実施例を挙げて本発明をより具体的に説明するが、本発明は下記の実施例に限定されるものではない。
A431細胞(浸潤性ヒト上皮ガン細胞)を10%血清入りDMEM(ダルベッコ変法イーグル培地)にて培養した。培養細胞を溶解バッファー(Lysis Buffer)(50mM トリス、0.5% TritonX-100、0.15M 塩化ナトリウム、pH4.5)にて可溶化し、スクレイパーにて回収した後、ピペッティングを行い、氷上で30分間静置した。その後、10,000rpmで10分遠心して不溶解物を除去し、上清を細胞抽出液として回収した。この細胞抽出液中のタンパク質量を、BCAタンパク質定量キット(BCA Protein Assay Kit、PIERCE、CA46141)にて測定した。
なお、以上の手順については、特表2003-502054号公報を参照されたい。
正常ヒト角化細胞を正常角化細胞用培地EpiLifeにて培養した。培地をPBSに一時的に置換してから50mJのUVBを照射し、1時間、2時間、4時間培養後に細胞を溶解バッファー(Lysis Buffer)にて可溶化したものを、紫外線照射群の試料溶液として用いた。また、培地をPBSに一時的に置換し、紫外線を照射しないものを、コントロール用溶液として用いた。これらの試料溶液及びコントロール用溶液を用い、実施例1と同様に処理を行って、OD475を測定した。得られたOD475の値に基づいて、実施例1と同様にしてヘパラナーゼ活性を評価した。その結果を図1に示す。紫外線を照射しないコントロールと比べて、紫外線照射群ではヘパラナーゼが有意に活性化することが明らかになった。
20代ヒト臀部に2MEDの紫外線を照射し、2日後に照射部位と近傍の紫外線を照射していない臀部皮膚をバイオプシーにて採取し、AMeX法にてパラフィンブロックを作製した。3μmの組織切片を作製し、ヘパラナーゼ及びヘパラン硫酸の免疫染色を実施した。得られた免疫染色画像を図2に示す。紫外線照射部位では、未照射部位と比較して、ヘパラナーゼの量が増加しており、また、ヘパラン硫酸の量は低下していることが明らかになった。
ヘパラン硫酸2mg及びアガロース10mgをPBS1ml(1%アガロース溶液)に加熱溶解してから、インサート(コーニング社製24ウェル用トランスウェル)に塗布することで、ヘパラン硫酸を含むシートを形成した。また、コントロールとして、ヘパラン硫酸を使用せずアガロースのみを使用した他は同様の手順により、ヘパラン硫酸を含まないシートを形成した。こうして、インサート内を表皮側、シートを基底膜、ウェルを真皮側に見立てた擬似皮膚モデルを作製した(図3a,b)。
Claims (6)
- 式(I)中、Rが炭素数2~4の直鎖又は分岐のアルキル基である、請求項1記載のヘパラナーゼ活性阻害剤。
- 式(I)の4-アルキルレソルシノールが、4-イソブチルレソルシノールである、請求項2記載のヘパラナーゼ活性阻害剤。
- ヘパラナーゼ活性に関連する状態又は症状を治療、改善又は予防するための医薬組成物であって、請求項1~3の何れか一項に記載のヘパラナーゼ活性阻害剤を有効成分として含んでなる医薬組成物。
- 創傷治癒、癌細胞の増殖若しくは転移の抑制、又は血管新生の抑制に用いられる、請求項4記載の医薬組成物。
- しわの形成を予防又は抑制するしわ改善剤であって、請求項1~3の何れか一項に記載のヘパラナーゼ活性阻害剤を有効成分として含んでなるしわ改善剤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10820610.3A EP2484349B1 (en) | 2009-09-30 | 2010-09-29 | 4-isobutylresorcinol, as heparanase-activity inhibitor, for preventing or suppressing the formation of wrinkles |
KR1020127005967A KR101736519B1 (ko) | 2009-09-30 | 2010-09-29 | 헤파라나제 활성 저해제 및 그것을 함유하는 주름 개선제 및 의약 조성물 |
CN201080043754.5A CN102573819A (zh) | 2009-09-30 | 2010-09-29 | 乙酰肝素酶活性抑制剂以及含有该乙酰肝素酶活性抑制剂的皱纹改善剂和药物组合物 |
ES10820610.3T ES2457236T3 (es) | 2009-09-30 | 2010-09-29 | 4-Isobutilresorcinol, como inhibidor de la actividad de la heparanasa, para prevenir o suprimir la formación de arrugas |
JP2011534287A JP5670340B2 (ja) | 2009-09-30 | 2010-09-29 | ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物 |
US13/261,236 US9101564B2 (en) | 2009-09-30 | 2010-09-29 | Heparanase activity inhibitor, wrinkle improving agent containing same, and pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009228209 | 2009-09-30 | ||
JP2009-228209 | 2009-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011040495A1 true WO2011040495A1 (ja) | 2011-04-07 |
Family
ID=43826307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/066997 WO2011040495A1 (ja) | 2009-09-30 | 2010-09-29 | ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9101564B2 (ja) |
EP (1) | EP2484349B1 (ja) |
JP (1) | JP5670340B2 (ja) |
KR (1) | KR101736519B1 (ja) |
CN (1) | CN102573819A (ja) |
ES (1) | ES2457236T3 (ja) |
TW (1) | TWI495465B (ja) |
WO (1) | WO2011040495A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2665006C1 (ru) * | 2017-02-28 | 2018-08-24 | Общество с ограниченной ответственностью "Супербаг Солюшенс" | Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3381907A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | Symmetrical 2-aminophenyl-benzazolyl-5-acetate compounds and their use as anti-heparanase |
EP3381908A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl)benzazole derivatives and their use as anti-heparanase |
EP3381906A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | Compounds for use as heparanase inhibitors |
EP3381898A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | Symmetrical tris-aryl-amide derivatives and their use as anti-heparanase |
EP3381897A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer |
EP3388439A1 (en) | 2017-04-11 | 2018-10-17 | Leadiant Biosciences SA | Biotin-conjugated n-acetyl glycol split heparin |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2093778A (en) | 1933-03-13 | 1937-09-21 | Monsanto Chemicals | Hydroxy-halogenated aryl compositions |
GB1581428A (en) | 1978-03-13 | 1980-12-10 | Conoco Inc | Alkylation of aromatic hydroxy compounds |
JPH0249715A (ja) | 1988-05-09 | 1990-02-20 | Kuraray Co Ltd | 美白剤 |
JPH02292213A (ja) * | 1989-05-02 | 1990-12-03 | Kuraray Co Ltd | 制癌剤 |
JPH0651619A (ja) | 1992-07-29 | 1994-02-25 | Mita Ind Co Ltd | 現像装置 |
JPH11335235A (ja) | 1998-05-22 | 1999-12-07 | Shiseido Co Ltd | 抗老化剤 |
JP2000503660A (ja) | 1996-01-19 | 2000-03-28 | ザ ユニバーシティ オブ ミシガン | 皮膚の光老化を抑制する方法 |
JP2001163794A (ja) | 1999-12-03 | 2001-06-19 | Shiseido Co Ltd | ヒアルロン酸産生促進剤および皮膚外用剤 |
JP2002167344A (ja) | 2000-11-29 | 2002-06-11 | Sumitomo Chem Co Ltd | 4−アルキルレゾルシンの製造方法 |
JP2003502054A (ja) | 1999-06-10 | 2003-01-21 | セントラル・マンチェスター・ヘルスケア・エヌエイチエス・トラスト | ヘパラナーゼアッセイ |
WO2003084302A2 (fr) | 2002-06-25 | 2003-10-16 | Shiseido Co Ltd | Agent anti-vieillissement |
JP2006124358A (ja) | 2004-11-01 | 2006-05-18 | Shiseido Co Ltd | 4−アルキルレソルシノール誘導体及びこれを有効成分とする美白剤 |
JP2007254412A (ja) | 2006-03-24 | 2007-10-04 | Kuraray Co Ltd | シワの予防及び/又は改善のための皮膚外用剤 |
WO2009123215A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社資生堂 | しわを防止または改善するための経口、注射、皮膚外用剤および美容方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0720451B2 (ja) * | 1988-07-18 | 1995-03-08 | 松下電器産業株式会社 | 調理器 |
BR9306816A (pt) * | 1992-07-28 | 1998-12-08 | Procter & Gamble | Composição farmaceutica para uso tópico contendo um polímero catiônico reticulado e um eter alcoxilado |
JPH07206669A (ja) | 1994-01-14 | 1995-08-08 | Nikken Food Kk | チロシナーゼ阻害活性剤 |
JP4615671B2 (ja) * | 2000-04-20 | 2011-01-19 | ポーラ化成工業株式会社 | 炎症存在下使用用のしわ形成又は皮膚の弾力喪失の防止剤 |
KR20070026306A (ko) * | 2003-10-28 | 2007-03-08 | 레디 유에스 테라퓨틱스 인코포레이티드 | 헤테로시클릴 화합물 및 그의 제조방법과 그의 용도 |
JP4831454B2 (ja) * | 2004-07-02 | 2011-12-07 | 独立行政法人産業技術総合研究所 | 皮膚外用剤 |
WO2009122540A1 (ja) | 2008-03-31 | 2009-10-08 | 株式会社資生堂 | しわを防止または改善するための経口、注射、皮膚外用剤および美容方法 |
-
2010
- 2010-09-29 JP JP2011534287A patent/JP5670340B2/ja active Active
- 2010-09-29 US US13/261,236 patent/US9101564B2/en active Active
- 2010-09-29 CN CN201080043754.5A patent/CN102573819A/zh active Pending
- 2010-09-29 ES ES10820610.3T patent/ES2457236T3/es active Active
- 2010-09-29 TW TW099133112A patent/TWI495465B/zh active
- 2010-09-29 EP EP10820610.3A patent/EP2484349B1/en active Active
- 2010-09-29 KR KR1020127005967A patent/KR101736519B1/ko active IP Right Grant
- 2010-09-29 WO PCT/JP2010/066997 patent/WO2011040495A1/ja active Application Filing
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2093778A (en) | 1933-03-13 | 1937-09-21 | Monsanto Chemicals | Hydroxy-halogenated aryl compositions |
GB1581428A (en) | 1978-03-13 | 1980-12-10 | Conoco Inc | Alkylation of aromatic hydroxy compounds |
JPH0249715A (ja) | 1988-05-09 | 1990-02-20 | Kuraray Co Ltd | 美白剤 |
JPH02292213A (ja) * | 1989-05-02 | 1990-12-03 | Kuraray Co Ltd | 制癌剤 |
JPH0651619A (ja) | 1992-07-29 | 1994-02-25 | Mita Ind Co Ltd | 現像装置 |
JP2000503660A (ja) | 1996-01-19 | 2000-03-28 | ザ ユニバーシティ オブ ミシガン | 皮膚の光老化を抑制する方法 |
JPH11335235A (ja) | 1998-05-22 | 1999-12-07 | Shiseido Co Ltd | 抗老化剤 |
JP2003502054A (ja) | 1999-06-10 | 2003-01-21 | セントラル・マンチェスター・ヘルスケア・エヌエイチエス・トラスト | ヘパラナーゼアッセイ |
JP2001163794A (ja) | 1999-12-03 | 2001-06-19 | Shiseido Co Ltd | ヒアルロン酸産生促進剤および皮膚外用剤 |
JP2002167344A (ja) | 2000-11-29 | 2002-06-11 | Sumitomo Chem Co Ltd | 4−アルキルレゾルシンの製造方法 |
WO2003084302A2 (fr) | 2002-06-25 | 2003-10-16 | Shiseido Co Ltd | Agent anti-vieillissement |
JP2006124358A (ja) | 2004-11-01 | 2006-05-18 | Shiseido Co Ltd | 4−アルキルレソルシノール誘導体及びこれを有効成分とする美白剤 |
JP2007254412A (ja) | 2006-03-24 | 2007-10-04 | Kuraray Co Ltd | シワの予防及び/又は改善のための皮膚外用剤 |
WO2009123215A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社資生堂 | しわを防止または改善するための経口、注射、皮膚外用剤および美容方法 |
Non-Patent Citations (6)
Title |
---|
EYAL ZCHARIA ET AL.: "Heparanase accelates wound angiogenesis and wound healing in mouse and rat models", THE FASEB JOURNAL, vol. 19, February 2005 (2005-02-01), pages 211 - 221, XP008154187 * |
ISRAEL VLODAVSKY ET AL.: "Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development", CANCER BIOLOGY, vol. 12, 2002, pages 121 - 129, XP008154125, DOI: doi:10.1006/scbi.2001.0420 * |
K. KAJIYA ET AL., AM. J. PATHOL., vol. 169, no. 4, 2006, pages 1496 - 1503 |
See also references of EP2484349A4 * |
VLODAVSKY I. ET AL., SEMIN CANCER BIOL., vol. 12, no. 2, 2002, pages 121 - 129 |
ZACHARIA E. ET AL., FASEB J., vol. 19, no. 2, February 2005 (2005-02-01), pages 211 - 21 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2665006C1 (ru) * | 2017-02-28 | 2018-08-24 | Общество с ограниченной ответственностью "Супербаг Солюшенс" | Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения |
WO2018160104A1 (ru) * | 2017-02-28 | 2018-09-07 | Юрий Александрович НИКОЛАЕВ | Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения |
Also Published As
Publication number | Publication date |
---|---|
CN102573819A (zh) | 2012-07-11 |
EP2484349A1 (en) | 2012-08-08 |
US9101564B2 (en) | 2015-08-11 |
TW201117805A (en) | 2011-06-01 |
EP2484349B1 (en) | 2014-04-02 |
ES2457236T3 (es) | 2014-04-25 |
KR101736519B1 (ko) | 2017-05-16 |
TWI495465B (zh) | 2015-08-11 |
KR20120093159A (ko) | 2012-08-22 |
JP5670340B2 (ja) | 2015-02-18 |
JPWO2011040495A1 (ja) | 2013-02-28 |
US20120184782A1 (en) | 2012-07-19 |
EP2484349A4 (en) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5593323B2 (ja) | ヘパラナーゼ活性阻害剤 | |
WO2011040495A1 (ja) | ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物 | |
JP5085321B2 (ja) | 皮膚外用剤 | |
US8859021B2 (en) | Skin appearance through gene manipulation | |
JP2011246353A (ja) | 皮膚外用剤 | |
JP2023060159A (ja) | 外用組成物 | |
US10377902B2 (en) | Crystallized red pigment, method of producing a recrystallized red pigment and a method for improving the appearance of or preventing wrinkles | |
CN111356468A (zh) | 包含黃漆木提取物作为有效成分的用于预防或治疗纤维化疾病的组合物 | |
KR20170073308A (ko) | 피부 개선용 조성물 | |
JP2011074024A (ja) | ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物 | |
WO2015159854A1 (ja) | アンチエイジング用皮膚外用剤 | |
JP2011074027A (ja) | ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物 | |
JP5133645B2 (ja) | セトラキサートを含有する美白剤 | |
KR101672841B1 (ko) | 피부 개선용 조성물 | |
JP7470270B2 (ja) | メラノソーム輸送阻害剤及び該輸送阻害剤を含有する皮膚外用剤 | |
KR101711512B1 (ko) | 피부 개선용 조성물 | |
KR101711513B1 (ko) | 피부 개선용 조성물 | |
JP6321506B2 (ja) | ヘパラナーゼ阻害剤による美白方法及び美白効果を有する物質の評価方法 | |
JP2011063520A (ja) | ヘパラナーゼ阻害剤による美白方法及び美白効果を有する物質の評価方法 | |
JP2010215516A (ja) | 皮膚外用剤および粘膜外用剤 | |
KR20170030832A (ko) | 빌로발라이드를 포함하는 피부 노화 방지용 피부외용제 조성물 | |
KR20150087142A (ko) | 피부 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080043754.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10820610 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011534287 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20127005967 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010820610 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13261236 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |